European Journal of Nutrition

, Volume 56, Issue 1, pp 343–353 | Cite as

Higher plasma quercetin levels following oral administration of an onion skin extract compared with pure quercetin dihydrate in humans

  • Constanze Burak
  • Verena Brüll
  • Peter Langguth
  • Benno F. Zimmermann
  • Birgit Stoffel-Wagner
  • Udo Sausen
  • Peter Stehle
  • Siegfried Wolffram
  • Sarah Egert
Original Contribution

Abstract

Purpose

To investigate the plasma kinetics of quercetin derived from hard capsules filled with onion skin extract powder or quercetin dihydrate in humans.

Methods

In a randomized, single-blind, diet-controlled crossover study, 12 healthy subjects (six men and six women) aged 21–33 years were administered a single oral supra-nutritional dose of approximately 163 mg quercetin derived from onion skin extract powder (containing 95.3 % of total flavonoids as quercetin aglycone) or quercetin dihydrate (134 mg quercetin aglycone equivalent). Blood samples were collected before and during a 24-h period after quercetin administration. The concentrations of quercetin and its two monomethylated derivatives, isorhamnetin (3′-O-methyl quercetin), and tamarixetin (4′-O-methyl quercetin), were measured using HPLC with fluorescence detection after plasma enzymatic treatment.

Results

The systemic availability, determined by comparing the plasma concentration–time curves of quercetin, was 4.8 times higher, and the maximum plasma concentration (Cmax) was 5.4 times higher after ingestion of the onion skin extract than after ingestion of pure quercetin dihydrate. By contrast, tmax did not differ significantly between the two formulations. The Cmax values for isorhamnetin and tamarixetin were 3.8 and 4.4 times higher, respectively, after administration of onion skin extract than after pure quercetin dihydrate. The plasma kinetics of quercetin were not significantly different in men and women.

Conclusion

Quercetin aglycone derived from onion skin extract powder is significantly more bioavailable than that from quercetin dihydrate powder filled hard capsules.

Keywords

Quercetin Bioavailability Onion Human study 

Abbreviations

AUC

Area under the plasma concentration–time curve

Cmax

Maximum plasma concentration

k

Elimination rate constant

tmax

Time at maximum quercetin plasma concentration Cmax

t1/2

Elimination half-life

References

  1. 1.
    Crozier A, Jaganath IB, Clifford MN (2009) Dietary phenolics: chemistry, bioavailability and effects on health. Nat Prod Rep 26:1001–1043CrossRefGoogle Scholar
  2. 2.
    U.S. Department of Agriculture (2013) USDA database for the flavonoid content of selected foods, release 3.1. http://www.ars.usda.gov/Services/docshtm?docid=6231
  3. 3.
    Erdman JW Jr, Balentine D, Arab L, Beecher G, Dwyer JT, Folts J, Harnly J, Hollman P, Keen CL, Mazza G, Messina M, Scalbert A, Vita J, Williamson G, Burrowes J (2007) Flavonoids and heart health: proceedings of the ILSI North America Flavonoids Workshop, May 31–June 1, 2005, Washington, DC. J Nutr 137:718S–737SGoogle Scholar
  4. 4.
    Scalbert A, Williamson G (2000) Dietary intake and bioavailability of polyphenols. J Nutr 130:2073S–2085SGoogle Scholar
  5. 5.
    Harwood M, Danielewska-Nikiel B, Borzelleca JF, Flamm GW, Williams GM, Lines TC (2007) A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol 45:2179–2205CrossRefGoogle Scholar
  6. 6.
    Mullen W, Edwards CA, Crozier A (2006) Absorption, excretion and metabolite profiling of methyl-, glucuronyl-, glucosyl- and sulpho-conjugates of quercetin in human plasma and urine after ingestion of onions. Br J Nutr 96:107–116CrossRefGoogle Scholar
  7. 7.
    Graf BA, Milbury PE, Blumberg JB (2005) Flavonols, flavones, flavanones, and human health: epidemiological evidence. J Med Food 8:281–290CrossRefGoogle Scholar
  8. 8.
    Boots AW, Haenen GR, Bast A (2008) Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol 585:325–337CrossRefGoogle Scholar
  9. 9.
    Wang X, Ouyang YY, Liu J, Zhao G (2014) Flavonoid intake and risk of CVD: a systematic review and meta-analysis of prospective cohort studies. Br J Nutr 111:1–11CrossRefGoogle Scholar
  10. 10.
    Egert S, Rimbach G (2011) Which sources of flavonoids: complex diets or dietary supplements? Adv Nutr 2:8–14CrossRefGoogle Scholar
  11. 11.
    Egert S, Bosy-Westphal A, Seiberl J, Kurbitz C, Settler U, Plachta-Danielzik S, Wagner AE, Frank J, Schrezenmeir J, Rimbach G, Wolffram S, Müller MJ (2009) Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study. Br J Nutr 102:1065–1074CrossRefGoogle Scholar
  12. 12.
    Egert S, Boesch-Saadatmandi C, Wolffram S, Rimbach G, Müller MJ (2010) Serum lipid and blood pressure responses to quercetin vary in overweight patients by apolipoprotein E genotype. J Nutr 140:278–284CrossRefGoogle Scholar
  13. 13.
    Brüll V, Burak C, Stoffel-Wagner B, Wolffram S, Nickenig G, Muller C, Langguth P, Alteheld B, Fimmers R, Naaf S, Zimmermann BF, Stehle P, Egert S (2015) Effects of a quercetin-rich onion skin extract on 24 h ambulatory blood pressure and endothelial function in overweight-to-obese patients with (pre-)hypertension: a randomised double-blinded placebo-controlled cross-over trial. Br J Nutr 114:1263–1277CrossRefGoogle Scholar
  14. 14.
    Boomgaarden I, Egert S, Rimbach G, Wolffram S, Muller MJ, Doring F (2010) Quercetin supplementation and its effect on human monocyte gene expression profiles in vivo. Br J Nutr 104:336–345CrossRefGoogle Scholar
  15. 15.
    Egert S, Wolffram S, Bosy-Westphal A, Boesch-Saadatmandi C, Wagner AE, Frank J, Rimbach G, Müller MJ (2008) Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans. J Nutr 138:1615–1621Google Scholar
  16. 16.
    Boesch-Saadatmandi C, Egert S, Schrader C, Coumol X, Barouki R, Muller MJ, Wolffram S, Rimbach G (2010) Effect of quercetin on paraoxonase 1 activity-studies in cultured cells, mice and humans. J Physiol Pharmacol 61:99–105Google Scholar
  17. 17.
    Egert S, Rimbach G, Müller MJ (2011) No evidence for a thermic effect of the dietary flavonol quercetin: a pilot study in healthy normal-weight women. Eur J Appl Physiol 111:869–873CrossRefGoogle Scholar
  18. 18.
    Olthof MR, Hollman PC, Vree TB, Katan MB (2000) Bioavailabilities of quercetin-3-glucoside and quercetin-4′-glucoside do not differ in humans. J Nutr 130:1200–1203Google Scholar
  19. 19.
    Hollman PC, de Vries JH, van Leeuwen SD, Mengelers MJ, Katan MB (1995) Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. Am J Clin Nutr 62:1276–1282Google Scholar
  20. 20.
    Wiczkowski W, Romaszko J, Bucinski A, Szawara-Nowak D, Honke J, Zielinski H, Piskula MK (2008) Quercetin from shallots (Allium cepa L. var. aggregatum) is more bioavailable than its glucosides. J Nutr 138:885–888Google Scholar
  21. 21.
    Egert S, Wolffram S, Schulze B, Langguth P, Hubbermann EM, Schwarz K, Adolphi B, Bosy-Westphal A, Rimbach G, Müller MJ (2012) Enriched cereal bars are more effective in increasing plasma quercetin compared with quercetin from powder-filled hard capsules. Br J Nutr 107:539–546CrossRefGoogle Scholar
  22. 22.
    Feuereisen MM, Hoppe J, Zimmermann BF, Weber F, Schulze-Kaysers N, Schieber A (2014) Characterization of phenolic compounds in Brazilian pepper (Schinus terebinthifolius Raddi) exocarp. J Agric Food Chem 62:6219–6226CrossRefGoogle Scholar
  23. 23.
    Bieger J, Cermak R, Blank R, de Boer VC, Hollman PC, Kamphues J, Wolffram S (2008) Tissue distribution of quercetin in pigs after long-term dietary supplementation. J Nutr 138:1417–1420Google Scholar
  24. 24.
    Sun SS, Chumlea WC, Heymsfield SB, Lukaski HC, Schoeller D, Friedl K, Kuczmarski RJ, Flegal KM, Johnson CL, Hubbard VS (2003) Development of bioelectrical impedance analysis prediction equations for body composition with the use of a multicomponent model for use in epidemiologic surveys. Am J Clin Nutr 77:331–340Google Scholar
  25. 25.
    Bruno RS, Leonard SW, Park SI, Zhao Y, Traber MG (2006) Human vitamin E requirements assessed with the use of apples fortified with deuterium-labeled alpha-tocopheryl acetate. Am J Clin Nutr 83:299–304Google Scholar
  26. 26.
    Linseisen J, Radtke J, Wolfram G (1997) Flavonoid intake of adults in a Bavarian subgroup of the national food consumption survey. Z Ernahrungswiss 36:403–412CrossRefGoogle Scholar
  27. 27.
    Zamora-Ros R, Forouhi NG, Sharp SJ, Gonzalez CA, Buijsse B, Guevara M, van der Schouw YT, Amiano P, Boeing H, Bredsdorff L, Fagherazzi G, Feskens EJ, Franks PW, Grioni S, Katzke V, Key TJ, Khaw KT, Kuhn T, Masala G, Mattiello A, Molina-Montes E, Nilsson PM, Overvad K, Perquier F, Redondo ML, Ricceri F, Rolandsson O, Romieu I, Roswall N, Scalbert A, Schulze M, Slimani N, Spijkerman AM, Tjonneland A, Tormo MJ, Touillaud M, Tumino R, van der AD, van Woudenbergh GJ, Langenberg C, Riboli E, Wareham NJ (2014) Dietary intakes of individual flavanols and flavonols are inversely associated with incident type 2 diabetes in European populations. J Nutr 144:335–343CrossRefGoogle Scholar
  28. 28.
    Moon YJ, Wang L, Dicenzo R, Morris ME (2008) Quercetin pharmacokinetics in humans. Biopharm Drug Dispos 29:205–217CrossRefGoogle Scholar
  29. 29.
    Guo Y, Bruno RS (2015) Endogenous and exogenous mediators of quercetin bioavailability. J Nutr Biochem 26:201–210CrossRefGoogle Scholar
  30. 30.
    Manach C, Williamson G, Morand C, Scalbert A, Remesy C (2005) Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 81:230S–242SGoogle Scholar
  31. 31.
    Williamson G, Manach C (2005) Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies. Am J Clin Nutr 81:243S–255SGoogle Scholar
  32. 32.
    Manach C, Scalbert A, Morand C, Remesy C, Jimenez L (2004) Polyphenols: food sources and bioavailability. Am J Clin Nutr 79:727–747Google Scholar
  33. 33.
    Erlund I, Kosonen T, Alfthan G, Maenpaa J, Perttunen K, Kenraali J, Parantainen J, Aro A (2000) Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. Eur J Clin Pharmacol 56:545–553CrossRefGoogle Scholar
  34. 34.
    Lee J, Mitchell AE (2012) Pharmacokinetics of quercetin absorption from apples and onions in healthy humans. J Agric Food Chem 60:3874–3881CrossRefGoogle Scholar
  35. 35.
    Krishnaiah YSR (2010) Pharmaceutical technologies for enhancing oral bioavailability of poorly soluble drugs. J Bioequiv Availab 2:28–36CrossRefGoogle Scholar
  36. 36.
    Guo Y, Mah E, Davis CG, Jalili T, Ferruzzi MG, Chun OK, Bruno RS (2013) Dietary fat increases quercetin bioavailability in overweight adults. Mol Nutr Food Res 57:896–905CrossRefGoogle Scholar
  37. 37.
    de Boer VC, Dihal AA, van der WH, Arts IC, Wolffram S, Alink GM, Rietjens IM, Keijer J, Hollman PC (2005) Tissue distribution of quercetin in rats and pigs. J Nutr 135:1718–1725Google Scholar
  38. 38.
    Zhu BT, Ezell EL, Liehr JG (1994) Catechol-O-methyltransferase-catalyzed rapid O-methylation of mutagenic flavonoids. Metabolic inactivation as a possible reason for their lack of carcinogenicity in vivo. J Biol Chem 269:292–299Google Scholar
  39. 39.
    Saha S, Hollands W, Needs PW, Ostertag LM, de Roos B, Duthie GG, Kroon PA (2012) Human O-sulfated metabolites of (−)-epicatechin and methyl-(−)-epicatechin are poor substrates for commercial aryl-sulfatases: implications for studies concerned with quantifying epicatechin bioavailability. Pharmacol Res 65:592–602CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Constanze Burak
    • 1
  • Verena Brüll
    • 1
  • Peter Langguth
    • 2
  • Benno F. Zimmermann
    • 3
    • 4
  • Birgit Stoffel-Wagner
    • 5
  • Udo Sausen
    • 6
  • Peter Stehle
    • 1
  • Siegfried Wolffram
    • 7
  • Sarah Egert
    • 1
  1. 1.Department of Nutrition and Food Sciences, Nutritional PhysiologyUniversity of BonnBonnGermany
  2. 2.Department of Biopharmaceutics and Pharmaceutical Technology, Institute of Pharmacy and BiochemistryJohannes Gutenberg UniversityMainzGermany
  3. 3.Institut Prof. Dr. Georg Kurz GmbHCologneGermany
  4. 4.Department of Nutrition and Food Sciences, Food Technology and Food BiotechnologyUniversity of BonnBonnGermany
  5. 5.Institute of Clinical Chemistry and Clinical PharmacologyUniversity Hospital BonnBonnGermany
  6. 6.Department of Anaesthesiology and Intensive Care MedicineUniversity Hospital BonnBonnGermany
  7. 7.Institute of Animal Nutrition and PhysiologyChristian-Albrechts-University KielKielGermany

Personalised recommendations